EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $28 at Mizuho

Mizuho analyst Graig Suvannavejh raised the price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) to $28.00 (from $26.00) while maintaining a Outperform rating.

The analyst comments "EYPT reported 2Q25 results last week, where highlights included the previously announced enrollment completion in the second P3 LUCIA study for Duravyu (a sustained release tyrosine kinase inhibitor/TKI product for wet AMD/wAMD) and, on 2Q results, lower OpEx. As a result of our model changes, we increase our 12-month PT on EYPT to $28 (vs. $26). Bigger picture, we continue to favor EYPT in the highly competitive wet AMD/wAMD space, given our view that EYPT: (1) has a more robust set of P2 data to support the potential of Duravyu; (2) has a more straightforward pivotal P3 clinical development program, one that is more representative of use in the real world; and (3) finds itself in the pole position with respect to when the first TKI-based product for wAMD might get approved. With valuation, in our view, still very attractive, we stay OP-rated."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy